4DMT to host webcast on interim 52-week data from Phase 2b of its PRISM clinical trial

(Image credit: AdobeStock/fizkes)

4D Molecular Therapeutics announced it will present the initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial. The trial is evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population. The data will be presented virtually at Angiogenesis, Exudation, and Degeneration 2025 on February 8, 2025.

4D-150 is a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF from the retina with a single intravitreal injection. Its goal is to free patients from burdensome injections while preserving vision.

The company will also host a webcast to examine the PRISM interim data and additional analyses from the 4D-150 program in wet AMD and diabetic macular edema (DME) on February 10, 2025. Dante Pieramici and Veeral Sheth, the principal investigators in the PRISM clinical trial, will also present on the webcast and host a Q&A.

Additionally, the presentation will be available on the 4DMT website.

Reference:

1. 4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population. Business Insider. Accessed February 3, 2025. 4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population | Markets Insider